Hourglass Capital’s Bristol-Myers Squibb BMY Stock Holding History

Hourglass Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,330	Closed	-$234K	–	136
2025 Q4	$234K	Buy	+4,330	New	+$208K	0.05%	110
2025 Q3	–	Sell	-4,330	Closed	-$200K	–	107
2025 Q2	$200K	Hold	4,330	–	–	0.05%	104
2025 Q1	$264K	Buy	4,330 +117	+3%	+$6.82K	0.07%	98
2024 Q4	$238K	Hold	4,213	–	–	0.07%	98
2024 Q3	$218K	Buy	+4,213	New	+$198K	0.06%	98
2024 Q2	–	Sell	-4,307	Closed	-$234K	–	105
2024 Q1	$234K	Buy	4,307 +94	+2%	+$4.79K	0.07%	95
2023 Q4	$216K	Hold	4,213	–	–	0.07%	94
2023 Q3	$245K	Hold	4,213	–	–	0.09%	89
2023 Q2	$269K	Hold	4,213	–	–	0.09%	86
2023 Q1	$292K	Hold	4,213	–	–	0.11%	85
2022 Q4	$303K	Hold	4,213	–	–	0.11%	83
2022 Q3	$300K	Hold	4,213	–	–	0.11%	88
2022 Q2	$324K	Buy	4,213 +1,213	+40%	+$92.4K	0.11%	87
2022 Q1	$219K	Buy	+3,000	New	+$201K	0.07%	99
2021 Q3	–	Sell	-3,000	Closed	-$200K	–	110
2021 Q2	$200K	Buy	+3,000	New	+$196K	0.05%	130
2020 Q4	–	Sell	-4,649	Closed	-$280K	–	126
2020 Q3	$280K	Hold	4,649	–	–	0.09%	105
2020 Q2	$273K	Hold	4,649	–	–	0.1%	104
2020 Q1	$259K	Hold	4,649	–	–	0.11%	97
2019 Q4	$298K	Hold	4,649	–	–	0.08%	96
2019 Q3	$236K	Hold	4,649	–	–	0.07%	103
2019 Q2	$211K	Hold	4,649	–	–	0.06%	102
2019 Q1	$222K	Sell	4,649 -1,500	-24%	-$74.7K	0.06%	100
2018 Q4	$320K	Hold	6,149	–	–	0.1%	88
2018 Q3	$382K	Hold	6,149	–	–	0.1%	89
2018 Q2	$340K	Hold	6,149	–	–	0.09%	88
2018 Q1	$389K	Hold	6,149	–	–	0.09%	88
2017 Q4	$377K	Hold	6,149	–	–	0.09%	91
2017 Q3	$392K	Hold	6,149	–	–	0.09%	84
2017 Q2	$343K	Hold	6,149	–	–	0.09%	86
2017 Q1	$334K	Hold	6,149	–	–	0.08%	86
2016 Q4	$359K	Hold	6,149	–	–	0.09%	82
2016 Q3	$332K	Hold	6,149	–	–	0.08%	81
2016 Q2	$452K	Hold	6,149	–	–	0.11%	81
2016 Q1	$393K	Hold	6,149	–	–	0.1%	83
2015 Q4	$423K	Hold	6,149	–	–	0.11%	82
2015 Q3	$364K	Hold	6,149	–	–	0.08%	86
2015 Q2	$409K	Hold	6,149	–	–	0.06%	90
2015 Q1	$397K	Hold	6,149	–	–	0.06%	92
2014 Q4	$363K	Sell	6,149 -5,000	-45%	-$282K	0.07%	90
2014 Q3	$571K	Sell	11,149 -517	-4%	-$25.8K	0.08%	86
2014 Q2	$566K	Hold	11,666	–	–	0.08%	86
2014 Q1	$606K	Buy	11,666 +2,166	+23%	+$115K	0.1%	87
2013 Q4	$505K	Hold	9,500	–	–	0.08%	89
2013 Q3	$440K	Sell	9,500 -6,000	-39%	-$263K	0.08%	89
2013 Q2	$693K	Buy	+15,500	New	+$673K	0.13%	77

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hourglass Capital's BMY Position: Q1 2026 in Review

Hourglass Capital sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 4,330 shares — an estimated $234K sold.

Hourglass Capital first reported a position in BMY in Q2 2013 and held it in 45 quarters. The position peaked at $693K in Q2 2013. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Hourglass Capital reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Hourglass Capital sold 4,330 Bristol-Myers Squibb shares in Q1 2026, an estimated $234K.
Hourglass Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 45 quarters.
Hourglass Capital's Bristol-Myers Squibb position peaked at $693K in Q2 2013.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Hourglass Capital's 13F filing for Q1 2026, filed 4 May 2026.